Bassam Janji

Luxembourg, LU, Luxembourg

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 85 publications

Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer.

Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer.

Journal: Journal for immunotherapy of cancer

Published: June 26, 2026

Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy.

Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy.

Journal: International journal of molecular sciences

Published: March 23, 2026

VPS34 in Autophagy, Cancer, and Cancer Therapy.

VPS34 in Autophagy, Cancer, and Cancer Therapy.

Journal: Cells

Published: February 25, 2026

Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm: assessing spatial response and unraveling resistance mechanisms.

Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm: assessing spatial response and unraveling resistance mechanisms.

Journal: Haematologica

Published: July 10, 2025

Unleashing anti-tumor immunity: Targeting the autophagy-related protein VPS34 to enhance STING agonist-based therapy.

Unleashing anti-tumor immunity: Targeting the autophagy-related protein VPS34 to enhance STING agonist-based therapy.

Journal: Autophagy reports

Published: May 21, 2025

Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model.

Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model.

Journal: Oncoimmunology

Published: April 18, 2025

Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors.

Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors.

Journal: Cell chemical biology

Published: February 27, 2025

Quantitative pre-clinical imaging of hypoxia and vascularity using MRI and PET.

Quantitative pre-clinical imaging of hypoxia and vascularity using MRI and PET.

Journal: Methods in cell biology

Published: January 17, 2025

Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34.

Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34.

Journal: Oncoimmunology

Published: June 14, 2024

Atypical chemokine receptor 2 expression is directly regulated by hypoxia inducible factor-1 alpha in cancer cells under hypoxia.

Atypical chemokine receptor 2 expression is directly regulated by hypoxia inducible factor-1 alpha in cancer cells under hypoxia.

Journal: Scientific reports

Published: May 23, 2024

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy.

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy.

Journal: Molecular oncology

Published: August 23, 2023

Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy.

Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy.

Journal: Seminars in cancer biology

Published: July 31, 2023

Showing 1-12 of 85

Last Updated: 09/26/2026